Pentadecapeptide BPC 157, in Clinical Trials as a Therapy for Inflammatory Bowel Disease (PL14736), Is Effective in the Healing of Colocutaneous Fistulas in Rats: Role of the Nitric Oxide-System

DOI Web Site 参考文献93件
  • Klicek Robert
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Sever Marko
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Radic Bozo
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Drmic Domagoj
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Kocman Ivan
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Zoricic Ivan
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Vuksic Tihomir
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Ivica Mihovil
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Barisic Ivan
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Ilic Spomenko
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Berkopic Lidija
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Vrcic Hrvoje
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Brcic Luka
    Department of Pathology, Medical School, University of Zagreb, Croatia
  • Blagaic Alenka Boban
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Coric Marijana
    Department of Pathology, Medical School, University of Zagreb, Croatia
  • Brcic Iva
    Department of Pathology, Medical School, University of Zagreb, Croatia
  • Rokotov Dinko Stancic
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Anic Tomislav
    Department of Pharmacology, Medical School, University of Zagreb, Croatia
  • Seiwerth Sven
    Department of Pathology, Medical School, University of Zagreb, Croatia
  • Sikiric Predrag
    Department of Pharmacology, Medical School, University of Zagreb, Croatia

この論文をさがす

抄録

We focused on the therapeutic effect of the stable gastric pentadecapeptide BPC 157 and how its action is related to nitric oxide (NO) in persistent colocutaneous fistula in rats (at 5 cm from anus, colon defect of 5 mm, skin defect of 5 mm); this peptide has been shown to be safe in clinical trials for inflammatory bowel disease (PL14736) and safe for intestinal anstomosis therapy. BPC 157 (10 μg/kg, 10 ng/kg) was applied i) in drinking water until the animals were sacrificed at post-operative day 1, 3, 5, 7, 14, 21, and 28; or ii) once daily intraperitoneally (first application 30 min following surgery, last 24 h before sacrifice) alone or with NG-nitro-<sc>L</sc>-arginine methyl ester (<sc>L</sc>-NAME) (5 mg/kg), <sc>L</sc>-arginine (200 mg/kg), and their combinations. Sulphasalazine (50 mg/kg) and 6-α-methylprednisolone (1 mg/kg) were given once daily intraperitoneally. BPC 157 accelerated parenterally or perorally the healing of colonic and skin defect, leading to the suitable closure of the fistula, macro/microscopically, biomechanically, and functionally (larger water volume sustained without fistula leaking). <sc>L</sc>-NAME aggravated the healing failure of colocutaneous fistulas, skin, and colon wounds (<sc>L</sc>-NAME groups). <sc>L</sc>-Arginine was effective only with blunted NO generation (<sc>L</sc>-NAME + <sc>L</sc>-arginine groups) but not without (<sc>L</sc>-arginine groups). All of the BPC 157 beneficial effects remained unchanged with blunted NO-generation (<sc>L</sc>-NAME + BPC 157 groups) and with NO substrate (<sc>L</sc>-arginine + BPC 157 groups) as well as <sc>L</sc>-NAME and <sc>L</sc>-arginine co-administration (<sc>L</sc>-NAME + <sc>L</sc>-arginine + BPC 157 groups). Sulphasalazine was only moderately effective, and corticosteroid even had an aggravating effect.<br>

収録刊行物

参考文献 (93)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ